Small Cell Lung Cancer: A New Era Is Beginning?

• Autres auteurs: Morabito, Alessandro (Éditeur intellectuel), Rolfo, Christian (Éditeur intellectuel)
• Format: Électronique Chapitre de livre
• Langue: anglais
• Publié: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Sujets: Medicine; immune checkpoint inhibitors; extensive-stage small cell lung cancer; nivolumab; ipilimumab; pembrolizumab; atezolizumab; durvalumab; chemotherapy; small-cell lung cancer; lobectomy; pneumonectomy; radiotherapy; multimodal treatment; immunotherapy; SCLC; PARP; DDR; ICB; synthetic lethality; SLFN11; STING; pathology and classification of SCLC; biology of SCLC; immune-checkpoint inhibitors in SCLC; small cell lung cancer; Immunotherapy; extensive disease; lurbinectedin; gene pathway; pathobiology; targeted therapy; circulating tumor cells; prognostic biomarker; targeted agents; n/a
• Accès en ligne: DOAB: download the publication; DOAB: description of the publication

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positi...